The Anti-inflammatory Effects of Harkány Medicinal Water

Rheumatoid Arthritis Clinical Trial

Official title: The Anti-inflammatory Effects of Harkány Medicinal Water

Status Recruiting

Clinical Trial Summary

The study aims to provide evidence on the effectiveness of Harkány medicinal water in psoriatic and rheumatoid arthritis patients using subjective and objective methods. It is a cross-over study, so first half of patients will receive medicinal water, the other half will receive tap water treatment, and after 6 months treatments will be repeated, but patients will receive the other type of water.

Clinical Trial Description

Several studies have shown that medicinal waters are highly effective in the treatment of many diseases. Existing clinical trials were unable to provide scientific evidence by using the highest international standards to justify the efficiency of thermal waters. Harkány medicinal water has been used for rheumatic, skin and locomotor diseases for more than 100 years. Its beneficial effects are indisputable. However, to introduce these effects, internationally high-level scientific methods and investigations are needed.

Psoriasis is among the most common dermatological diseases worldwide. Its significance is emphasized by adverse effects on quality of life, caused by chronic pain, physical and psychical disability due to psoriatic plaques. Former studies revealed an increased risk of inflammatory bowel disease, cardiovascular disease and certain types of cancer. Moreover, excessive oxidative stress can be responsible for the onset of psoriasis complications.

Rheumatoid arthritis (RA) is an autoimmune disease responsible for significant morbidity, characterized by articular inflammation. Oxidative stress is a key marker for determining pathophysiology of patients with RA.

The pathophysiological link between these conditions is the presence of excessive oxidative stress.

Subjective methods will include questionnaires, objective markers of disease severity will include the measurement of biomarkers from blood samples. ;

Related Conditions & MeSH terms

• Psoriasis
• Rheumatoid Arthritis

• NCT number: NCT04275206
• Study type: Interventional
• Source: University of Pecs
• Contact: Katalin Dr Szendi, MD, PhD
• Phone: +3672536396
• Email: szkata82@yahoo.co.uk
• Status: Recruiting
• Phase: N/A
• Start date: June 1, 2020
• Completion date: November 30, 2023